Sofosbuvir-based Regimens in HIV/HCV Coinfected Patients after Liver Transplantation: Results from the ANRS CO23 CUPILT Study.

Background: A recurrence of hepatitis C virus after liver transplantation affects survival in HIV/HCV coinfected patients. This study assessed the efficacy and safety of sofosbuvir-based regimens in HIV/HCV coinfected patients following liver transplantation. Methods: 29 HIV/HCV coinfected transplanted patients receiving tacrolimus, cyclosporine or everolimus-based immunosuppressive therapy were enrolled in the CUPILT cohort. Their antiviral treatment combined sofosbuvir, daclatasvir with or without ribavirin (n=10/n=6), or sofosbuvir, ledipasvir with or without ribavirin (n=2/n=11). Results: The median delay between liver transplantation and treatment initiation was 37.5 months (IQR 14.4-99.2). The breakdown of HCV genotypes was: G1: 22 patients (75.9%), G3: 3 patients (10.3%) and G4: 4 patients (13.8%). The treatment indications were HCV recurrence (>= F1 n=23) or fibrosing cholestatic hepatitis (n=6). Before starting sofosbuvir, the HCV viral load and CD4 count were 6.7 log10 IU/mL (IQR 5.9-7.2), and 342 cells/mm3 (IQR 172-483), respectively. At W4, the HCV viral load was

http://ift.tt/2xHmo6F